MedTrace Logo

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

NCT05467176 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 999

Last updated 2026-04-08

No results posted yet for this study

Summary

This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.

Conditions

Interventions

DRUG

Relugolix

Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Sumitomo Pharma

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-04
Primary Completion
2026-06-30
Completion
2026-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467176 on ClinicalTrials.gov